Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Timperi, Eleonora ^a   Pacella, Ilenia ^a   Schinzari, Valeria ^a   Focaccetti, Chiara ^a   Sacco, Luca ^a   Farelli, Francesco ^a   Caronna, Roberto ^a   Del Bene, Gabriella ^a   Longo, Flavia ^a   Ciardi, Antonio ^b   Morelli, Sergio ^a   Vestri, Anna Rita ^c   Chirletti, Piero ^a   Barnaba, Vincenzo ^a,d,e   Piconese, Silvia ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Pasteur Institute   (Italy)

^e ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

CD39; colorectal cancer; helios; OX40; T follicular regulatory; Tfh; Th17; tregs

Indexed keywords

CD134 ANTIGEN; CD39 ANTIGEN; CYTOKINE; INTERLEUKIN 17;

AGED; ARTICLE; BONE MARROW SUPPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; CELL SELECTION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC MARKER; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUCOSA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84976382144     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1175800     Document Type: Article

References (61)

1. S.Piconese, E.Timperi, I.Pacella, V.Schinzari, C.Tripodo, M.Rossi, N.Guglielmo, G.Mennini, G.L.Grazi, S.Filippo et al. Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology 2014; 60:1494-507; PMID:24756990; http://dx.doi.org/10.1002/hep.27188
2. R.J.deLeeuw, S.E.Kost, J.A.Kakal, B.H.Nelson. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer:a critical review of the literature. Clin Cancer Res 2012; 18:3022-9; PMID:22510350; http://dx.doi.org/10.1158/1078-0432.CCR-11-3216
3. S.Ladoire, F.Martin, F.Ghiringhelli. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas:the paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60:909-18; PMID:21644034; http://dx.doi.org/10.1007/s00262-011-1046-y
4. P.Salama, M.Phillips, F.Grieu, M.Morris, N.Zeps, D.Joseph, C.Platell, B.Iacopetta. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27:186-92; PMID:19064967; http://dx.doi.org/10.1200/JCO.2008.18.7229
5. A.M.Gallimore, A.K.Simon. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 2008; 27:5886-93; PMID:18836469; http://dx.doi.org/10.1038/onc.2008.269
6. A.L.Geis, H.Fan, X.Wu, S.Wu, D.L.Huso, J.L.Wolfe, C.L.Sears, D.M.Pardoll, F.Housseau. Regulatory T-cell Response to Enterotoxigenic Bacteroides fragilis Colonization Triggers IL17-Dependent Colon Carcinogenesis. Cancer Discov 2015; 5:1098-109; PMID:26201900; http://dx.doi.org/10.1158/2159-8290.CD-15-0447
7. G.Betts, E.Jones, S.Junaid, T.El-Shanawany, M.Scurr, P.Mizen, M.Kumar, S.Jones, B.Rees, G.Williams et al. Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012; 61:1163-71; PMID:22207629; http://dx.doi.org/10.1136/gutjnl-2011-300970
8. A.Bonertz, J.Weitz, D.H.Pietsch, N.N.Rahbari, C.Schlude, Y.Ge, S.Juenger, I.Vlodavsky, K.Khazaie, D.Jaeger et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311-21; PMID:19809157; http://dx.doi.org/10.1172/JCI39608
9. S.L.Clarke, G.J.Betts, A.Plant, K.L.Wright, T.M.El-Shanawany, R.Harrop, J.Torkington, B.I.Rees, G.T.Williams, A.M.Gallimore et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006; 1:e129; PMID:17205133; http://dx.doi.org/10.1371/journal.pone.0000129
10. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pages, M.Tosolini, M.Camus, A.Berger, P.Wind et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
11. G.Di Caro, F.Bergomas, F.Grizzi, A.Doni, P.Bianchi, A.Malesci, L.Laghi, P.Allavena, A.Mantovani, F.Marchesi. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res 2014; 20:2147-58; PMID:24523438; http://dx.doi.org/10.1158/1078-0432.CCR-13-2590
12. P.T.Sage, A.H.Sharpe. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol 2015; 36:410-8; PMID:26091728; http://dx.doi.org/10.1016/j.it.2015.05.005
13. N.R.Blatner, M.F.Mulcahy, K.L.Dennis, D.Scholtens, D.J.Bentrem, J.D.Phillips, S.Ham, B.P.Sandall, M.W.Khan, D.M.Mahvi et al. Expression of RORgammat marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med 2012; 4:164ra59; PMID:23241743; http://dx.doi.org/10.1126/scitranslmed.3004566
14. M.Miyara, Y.Yoshioka, A.Kitoh, T.Shima, K.Wing, A.Niwa, C.Parizot, C.Taflin, T.Heike, D.Valeyre et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911; PMID:19464196; http://dx.doi.org/10.1016/j.immuni.2009.03.019
15. H.Takatori, H.Kawashima, A.Matsuki, K.Meguro, S.Tanaka, T.Iwamoto, Y.Sanayama, N.Nishikawa, T.Tamachi, K.Ikeda et al. Helios Enhances Treg Cell Function in Cooperation With FoxP3. Arthritis Rheumatol 2015; 67:1491-502; PMID:25733061; http://dx.doi.org/10.1002/art.39091
16. H.J.Kim, R.A.Barnitz, T.Kreslavsky, F.D.Brown, H.Moffett, M.E.Lemieux, Y.Kaygusuz, T.Meissner, T.A.Holderried, S.Chan et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science 2015; 350:334-9; PMID:26472910; http://dx.doi.org/10.1126/science.aad0616
17. M.J.Barnes, F.Powrie. Regulatory T cells reinforce intestinal homeostasis. Immunity 2009; 31:401-11; PMID:19766083; http://dx.doi.org/10.1016/j.immuni.2009.08.011
18. J.D.Waight, S.Takai, B.Marelli, G.Qin, K.W.Hance, D.Zhang, R.Tighe, Y.Lan, K.M.Lo, H.Sabzevari et al. Cutting edge:epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans. J Immunol 2015; 194:878-82; PMID:25548231; http://dx.doi.org/10.4049/jimmunol.1402725
19. T.Griseri, M.Asquith, C.Thompson, F.Powrie. OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med 2010; 207:699-709; PMID:20368580; http://dx.doi.org/10.1084/jem.20091618
20. S.Piconese, P.Pittoni, A.Burocchi, A.Gorzanelli, A.Care, C.Tripodo, M.P.Colombo. A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. Eur J Immunol 2010; 40:2902-13; PMID:20806292; http://dx.doi.org/10.1002/eji.201040505
21. M.Croft. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010; 28:57-78; PMID:20307208; http://dx.doi.org/10.1146/annurev-immunol-030409-101243
22. A.Kroemer, X.Xiao, M.D.Vu, W.Gao, K.Minamimura, M.Chen, T.Maki, X.C.Li. OX40 controls functionally different T cell subsets and their resistance to depletion therapy. J Immunol 2007; 179:5584-91; PMID:17911646; http://dx.doi.org/10.4049/jimmunol.179.8.5584
23. A.Rissiek, I.Baumann, A.Cuapio, A.Mautner, M.Kolster, P.C.Arck, A.Dodge-Khatami, H.W.Mittrucker, F.Koch-Nolte, F.Haag et al. The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation. J Autoimmun 2015; 58:12-20; PMID:25640206; http://dx.doi.org/10.1016/j.jaut.2014.12.007
24. P.J.Schuler, B.Schilling, M.Harasymczuk, T.K.Hoffmann, J.Johnson, S.Lang, T.L.Whiteside. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 2012; 42:1876-85; PMID:22585562; http://dx.doi.org/10.1002/eji.201142347
25. D.J.Friedman, B.M.Kunzli, A.YIAR, J.Sevigny, P.O.Berberat, K.Enjyoji, E.Csizmadia, H.Friess, S.C.Robson. From the Cover:CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A 2009; 106:16788-93; PMID:19805374; http://dx.doi.org/10.1073/pnas.0902869106
26. I.Kryczek, K.Wu, E.Zhao, S.Wei, L.Vatan, W.Szeliga, E.Huang, J.Greenson, A.Chang, J.Rolinski et al. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol 2011; 186:4388-95; PMID:21357259; http://dx.doi.org/10.4049/jimmunol.1003251
27. D.Valmori, C.Raffin, I.Raimbaud, M.Ayyoub. Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci U S A 2010; 107:19402-7; PMID:20962281; http://dx.doi.org/10.1073/pnas.1008247107
28. A.Bai, A.Moss, E.Kokkotou, A.Usheva, X.Sun, A.Cheifetz, Y.Zheng, M.S.Longhi, W.Gao, Y.Wu et al. CD39 and CD161 modulate Th17 responses in Crohn's disease. J Immunol 2014; 193:3366-77; PMID:25172498; http://dx.doi.org/10.4049/jimmunol.1400346
29. C.Raffin, P.Pignon, C.Celse, E.Debien, D.Valmori, M.Ayyoub. Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1beta by downregulating their suppressor functions. J Immunol 2013; 191:4619-27; PMID:24068664; http://dx.doi.org/10.4049/jimmunol.1301378
30. E.Sefik, N.Geva-Zatorsky, S.Oh, L.Konnikova, D.Zemmour, A.M.McGuire, D.Burzyn, A.Ortiz-Lopez, M.Lobera, J.Yang et al. Mucosal Immunology. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science 2015; 349:993-7; PMID:26272906; http://dx.doi.org/10.1126/science.aaa9420
31. C.Jacquemin, N.Schmitt, C.Contin-Bordes, Y.Liu, P.Narayanan, J.Seneschal, T.Maurouard, D.Dougall, E.S.Davizon, H.Dumortier et al. OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response. Immunity 2015; 42:1159-70; PMID:26070486; http://dx.doi.org/10.1016/j.immuni.2015.05.012
32. M.Tosolini, A.Kirilovsky, B.Mlecnik, T.Fredriksen, S.Mauger, G.Bindea, A.Berger, P.Bruneval, W.H.Fridman, F.Pages et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263-71; PMID:21303976; http://dx.doi.org/10.1158/0008-5472.CAN-10-2907
33. S.I.Grivennikov, K.Wang, D.Mucida, C.A.Stewart, B.Schnabl, D.Jauch, K.Taniguchi, G.Y.Yu, C.H.Osterreicher, K.E.Hung et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491:254-8; PMID:23034650; http://dx.doi.org/10.1038/nature11465
34. K.Wang, M.K.Kim, G.Di Caro, J.Wong, S.Shalapour, J.Wan, W.Zhang, Z.Zhong, E.Sanchez-Lopez, L.W.Wu et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 2014; 41:1052-63; PMID:25526314; http://dx.doi.org/10.1016/j.immuni.2014.11.009
35. G.Bindea, B.Mlecnik, M.Tosolini, A.Kirilovsky, M.Waldner, A.C.Obenauf, H.Angell, T.Fredriksen, L.Lafontaine, A.Berger et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
36. F.A.Sinicrope, R.L.Rego, S.M.Ansell, K.L.Knutson, N.R.Foster, D.J.Sargent. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137:1270-9; PMID:19577568; http://dx.doi.org/10.1053/j.gastro.2009.06.053
37. X.Sun, Y.Wu, W.Gao, K.Enjyoji, E.Csizmadia, C.E.Muller, T.Murakami, S.C.Robson. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterol 2010; 139:1030-40; PMID:20546740; http://dx.doi.org/10.1053/j.gastro.2010.05.007
38. D.Vignali. How many mechanisms do regulatory T cells need? Eur J Immunol 2008; 38:908-11; PMID:18395857; http://dx.doi.org/10.1002/eji.200738114
39. P.J.Schuler, M.Harasymczuk, B.Schilling, S.Lang, T.L.Whiteside. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011; 369:59-68; PMID:21513715; http://dx.doi.org/10.1016/j.jim.2011.04.004
40. A.M.Thornton, P.E.Korty, D.Q.Tran, E.A.Wohlfert, P.E.Murray, Y.Belkaid, E.M.Shevach. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184:3433-41; PMID:20181882; http://dx.doi.org/10.4049/jimmunol.0904028
41. R.A.Gottschalk, E.Corse, J.P.Allison. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol 2012; 188:976-80; PMID:22198953; http://dx.doi.org/10.4049/jimmunol.1102964
42. S.Floess, J.Freyer, C.Siewert, U.Baron, S.Olek, J.Polansky, K.Schlawe, H.D.Chang, T.Bopp, E.Schmitt, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5:e38; PMID:17298177; http://dx.doi.org/10.1371/journal.pbio.0050038
43. Y.C.Kim, R.Bhairavabhotla, J.Yoon, A.Golding, A.M.Thornton, D.Q.Tran, E.M.Shevach. Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood 2012; 119:2810-8; PMID:22294730; http://dx.doi.org/10.1182/blood-2011-09-377895
44. T.Miyao, S.Floess, R.Setoguchi, H.Luche, H.J.Fehling, H.Waldmann, J.Huehn, S.Hori. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012; 36:262-75; PMID:22326580; http://dx.doi.org/10.1016/j.immuni.2011.12.012
45. N.Ohkura, M.Hamaguchi, H.Morikawa, K.Sugimura, A.Tanaka, Y.Ito, M.Osaki, Y.Tanaka, R.Yamashita, N.Nakano et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 2012; 37:785-99; PMID:23123060; http://dx.doi.org/10.1016/j.immuni.2012.09.010
46. R.Roychoudhuri, R.L.Eil, N.P.Restifo. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol 2015; 33:101-11; PMID:25728990; http://dx.doi.org/10.1016/j.coi.2015.02.003
47. N.R.West, S.E.Kost, S.D.Martin, K.Milne, R.J.Deleeuw, B.H.Nelson, P.H.Watson. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 2013; 108:155-62; PMID:23169287; http://dx.doi.org/10.1038/bjc.2012.524
48. X.Chen, J.J.Oppenheim. Th17 cells and Tregs:unlikely allies. J Leukoc Biol 2014; 95:723-31; PMID:24563509; http://dx.doi.org/10.1189/jlb.1213633
49. L.Xu, A.Kitani, I.Fuss, W.Strober. Cutting edge:regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 2007; 178:6725-9; PMID:17513718; http://dx.doi.org/10.4049/jimmunol.178.11.6725
50. D.Franceschini, M.Paroli, V.Francavilla, M.Videtta, S.Morrone, G.Labbadia, A.Cerino, M.U.Mondelli, V.Barnaba. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009; 119:551-64; PMID:19229109; http://dx.doi.org/10.1172/JCI36604
51. A.Facciabene, X.Peng, I.S.Hagemann, K.Balint, A.Barchetti, L.P.Wang, P.A.Gimotty, C.B.Gilks, P.Lal, L.Zhang et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475:226-30; PMID:21753853; http://dx.doi.org/10.1038/nature10169
52. N.Arpaia, J.A.Green, B.Moltedo, A.Arvey, S.Hemmers, S.Yuan, P.M.Treuting, A.Y.Rudensky. A Distinct Function of Regulatory T Cells in Tissue Protection. Cell 2015; 162:1078-89; PMID:26317471; http://dx.doi.org/10.1016/j.cell.2015.08.021
53. D.C.Bento, E.Jones, S.Junaid, J.Tull, G.T.Williams, A.Godkin, A.Ager, A.Gallimore. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. Oncoimmunology 2015; 4:e974374; PMID:25949892; http://dx.doi.org/10.4161/2162402X.2014.974374
54. N.S.Joshi, E.H.Akama-Garren, Y.Lu, D.Y.Lee, G.P.Chang, A.Li, M.DuPage, T.Tammela, N.R.Kerper, A.F.Farago et al. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity 2015; 43:579-90; PMID:26341400; http://dx.doi.org/10.1016/j.immuni.2015.08.006
55. B.D.Curti, M.Kovacsovics-Bankowski, N.Morris, E.Walker, L.Chisholm, K.Floyd, J.Walker, I.Gonzalez, T.Meeuwsen, B.A.Fox et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013; 73:7189-98; PMID:24177180; http://dx.doi.org/10.1158/0008-5472.CAN-12-4174
56. H.B.Jie, P.J.Schuler, S.C.Lee, R.M.Srivastava, A.Argiris, S.Ferrone, T.L.Whiteside, R.L.Ferris. CTLA-4(+) Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res 2015; 75:2200-10; PMID:25832655; http://dx.doi.org/10.1158/0008-5472.CAN-14-2788
57. P.J.Schuler, M.Harasymczuk, B.Schilling, Z.Saze, L.Strauss, S.Lang, J.T.Johnson, T.L.Whiteside. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res 2013; 19:6585-96; PMID:24097865; http://dx.doi.org/10.1158/1078-0432.CCR-13-0900
58. A.J.Rech, R.Mick, D.E.Kaplan, K.M.Chang, S.M.Domchek, R.H.Vonderheide. Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 2010; 59:599-607; PMID:19855964; http://dx.doi.org/10.1007/s00262-009-0780-x
59. P.R.Rogers, J.Song, I.Gramaglia, N.Killeen, M.Croft. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001; 15:445-55; PMID:11567634; http://dx.doi.org/10.1016/S1074-7613(01)00191-1
60. T.Kanai, M.Watanabe, A.Okazawa, K.Nakamaru, M.Okamoto, M.Naganuma, H.Ishii, M.Ikeda, M.Kurimoto, T.Hibi. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterol 2000; 119:1514-23; PMID:11113073; http://dx.doi.org/10.1053/gast.2000.20260
61. R.Spreafico, M.Rossetti, T.van den Broek, N.J.Jansen, H.Zhang, M.Moshref, B.Prakken, J.van Loosdregt, F.van Wijk, S.Albani. A sensitive protocol for FOXP3 epigenetic analysis in scarce human samples. Eur J Immunol 2014; 44:3141-3; PMID:25042685; http://dx.doi.org/10.1002/eji.201444627